Technology Area: Therapeutics
441 Results for 'Therapeutics'
- Technologies (64)
- Collaborations (4)
- Team (0)
- News (292)
- Pages (0)
- Multimedia (81)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 64
-
Injectable Hydrogel Adhesive for Improved Muscle Regeneration
A super-strong, stretchy, and self-healing biomaterial that adheres to muscles and helps them heal faster after injury. -
Ropirio: Novel Treatments Targeting the Lymphatic System
Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more. -
DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics. -
i3 Center: Biomaterials to Create T Cell Immunity
Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.
News 292
Multimedia 81
-
Audio/PodcastSeqVerify: A New Easily Accessible Tool for Comprehensive Cell Line Quality Assessment – The Stem Cell ReportDuring the last decade, advances in genome editing and pluripotent stem cell (PSC) culture have let researchers generate edited PSC lines to study a wide variety of biological questions. However, abnormalities in cell lines such as aneuploidy, mutations, on-target and off-target editing errors, and microbial contamination can arise during PSC culture or due to undesired... -
Video/AnimationDoriNano – Improved DNA Origami Nanodelivery to Fight Cancer and Other DiseasesWe’re developing DNA Origami nanodelivery, which is transforming nanoparticle industry. Developed at the Dana Farber Cancer Institute and the Wyss Institute at Harvard University, this innovative approach overcomes the challenges of other nanoparticles, offering stability, high drug loading capacity, nano-scale control of cargo spacing, and more – making it a highly customizable solution for delivering... -
Video/AnimationDeep-dive Molecular Blueprinting of Therapeutic Nanostructures | Anastasia ErshovaAnastasia Ershova, a scientist at the Wyss, introduces the innovative field of bionanotechnology. In this talk from LabWeek Field Building, she explores how this cutting-edge science is revolutionizing therapeutics and diagnostics by building molecules that interact with the body in novel ways. Ershova discusses DNA nanotechnology, where DNA is used as a material to create... -
Video/AnimationAminoX: Making Better Protein Drugs, Quicker and CheaperA synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University -
Video/AnimationMice Don’t Menstruate: Reimagining Women’s Health Using Organ Chips with Dr. Donald IngberIn this episode, host Sharon Kedar, Co-Founder of Northpond Ventures, is joined by Dr. Donald Ingber, Founding Director at Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Ingber’s commitment to following his passion has led him to countless medical and technological breakthroughs, including Organ Chip technology. These incredible chips recreate the structure and... -
Video/AnimationAtlantic Health Research Spotlight: Finding Balance in Bipolar Disorder Through Drug Prediction and Organoid-Based Drug ScreeningInnovation has disrupted care as we know it. Challenges with access, complex diseases, and care delivery persist, but so do areas of opportunity for emerging tech and discoveries. The Atlantic explored gene editing, artificial intelligence, climate change, weight-loss and diabetes treatments, and more at their Annual Health Summit. The Wyss’ Director of Synthetic Biology, Jenny...